FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128421946> ?p ?o ?g. }

• W2128421946 endingPage "588" @default.
• W2128421946 startingPage "577" @default.
• W2128421946 abstract "Combining the β3-adrenoceptor agonist mirabegron and the antimuscarinic (AM) agent solifenacin may improve efficacy in the treatment of overactive bladder (OAB) while reducing the AM side effects.The primary objective was to evaluate the efficacy of combinations of solifenacin/mirabegron compared with solifenacin 5mg monotherapy. The secondary objective was to explore the dose-response relationship and the safety/tolerability compared with placebo and monotherapy.A phase 2, factorial design, randomised, double-blind, parallel-group, placebo- and monotherapy-controlled trial, conducted at 141 sites in 20 European countries. Male and female patients were aged ≥18 yr with symptoms of OAB for ≥3 mo.A total of 1306 patients (66.4% female) were randomised to 12 wk of treatment in 1 of 12 groups: 6 combination groups (solifenacin 2.5, 5, or 10 mg plus mirabegron 25 or 50 mg), 5 monotherapy groups (solifenacin 2.5, 5, or 10 mg, or mirabegron 25 or 50 mg), or placebo.Change from baseline to end of treatment in mean volume voided per micturition (MVV) (primary end point) and mean numbers of micturitions per 24 h, incontinence episodes per 24 h, and urgency episodes per 24 h were analysed using an analysis of covariance model. Safety assessments included treatment-emergent adverse events (TEAEs), blood pressure, pulse rate, postvoid residual (PVR) volume, and laboratory and electrocardiography (ECG) parameters.Compared with solifenacin 5 mg monotherapy, all combinations with solifenacin 5 or 10 mg significantly improved MVV, with adjusted differences ranging from 18.0 ml (95% confidence interval [CI], 5.4-30.0) to 26.3 ml (95% CI, 12.0-41.0). Three combination groups significantly reduced micturition frequency compared with solifenacin 5 mg, ranging from -0.80 (95% CI, -1.39 to -0.22) to -0.98 (95% CI, -1.68 to -0.27). Five of six combinations significantly reduced urgency episodes compared with solifenacin 5 mg, ranging from -0.98 (95% CI, -1.78, to -0.18) to -1.37 (95% CI, -2.03 to -0.70). No dose-related trends in TEAEs, blood pressure, pulse rate, PVR volume, or laboratory or ECG parameters were observed between combination and monotherapy groups, although the incidence of constipation was slightly increased with combination therapy.Combination therapy with solifenacin/mirabegron significantly improved MVV, micturition frequency, and urgency compared with solifenacin 5 mg monotherapy. All combinations were well tolerated, with no important additional safety findings compared with monotherapy or placebo.To improve treatment of overactive bladder (OAB), mirabegron/solifenacin in combination was compared with each drug alone and placebo. Combination therapy improved OAB symptoms and had similar safety and acceptability.Clinical trials.gov: NCT01340027." @default.
• W2128421946 created "2016-06-24" @default.
• W2128421946 creator A5025714543 @default.
• W2128421946 creator A5046089099 @default.
• W2128421946 creator A5053685634 @default.
• W2128421946 creator A5064978476 @default.
• W2128421946 creator A5065452127 @default.
• W2128421946 creator A5070559261 @default.
• W2128421946 creator A5073125739 @default.
• W2128421946 creator A5085188200 @default.
• W2128421946 creator A5090695716 @default.
• W2128421946 creator A5091855331 @default.
• W2128421946 date "2015-03-01" @default.
• W2128421946 modified "2023-10-18" @default.
• W2128421946 title "Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)" @default.
• W2128421946 cites W1538509597 @default.
• W2128421946 cites W1972477468 @default.
• W2128421946 cites W1979336330 @default.
• W2128421946 cites W1980254319 @default.
• W2128421946 cites W2002325903 @default.
• W2128421946 cites W2005256857 @default.
• W2128421946 cites W2008344118 @default.
• W2128421946 cites W2022422644 @default.
• W2128421946 cites W2067945145 @default.
• W2128421946 cites W2082897746 @default.
• W2128421946 cites W2103055084 @default.
• W2128421946 cites W2110991424 @default.
• W2128421946 cites W2136500714 @default.
• W2128421946 cites W2148759898 @default.
• W2128421946 cites W2164869770 @default.
• W2128421946 doi "https://doi.org/10.1016/j.eururo.2014.02.012" @default.
• W2128421946 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24612659" @default.
• W2128421946 hasPublicationYear "2015" @default.
• W2128421946 type Work @default.
• W2128421946 sameAs 2128421946 @default.
• W2128421946 citedByCount "190" @default.
• W2128421946 countsByYear W21284219462014 @default.
• W2128421946 countsByYear W21284219462015 @default.
• W2128421946 countsByYear W21284219462016 @default.
• W2128421946 countsByYear W21284219462017 @default.
• W2128421946 countsByYear W21284219462018 @default.
• W2128421946 countsByYear W21284219462019 @default.
• W2128421946 countsByYear W21284219462020 @default.
• W2128421946 countsByYear W21284219462021 @default.
• W2128421946 countsByYear W21284219462022 @default.
• W2128421946 countsByYear W21284219462023 @default.
• W2128421946 crossrefType "journal-article" @default.
• W2128421946 hasAuthorship W2128421946A5025714543 @default.
• W2128421946 hasAuthorship W2128421946A5046089099 @default.
• W2128421946 hasAuthorship W2128421946A5053685634 @default.
• W2128421946 hasAuthorship W2128421946A5064978476 @default.
• W2128421946 hasAuthorship W2128421946A5065452127 @default.
• W2128421946 hasAuthorship W2128421946A5070559261 @default.
• W2128421946 hasAuthorship W2128421946A5073125739 @default.
• W2128421946 hasAuthorship W2128421946A5085188200 @default.
• W2128421946 hasAuthorship W2128421946A5090695716 @default.
• W2128421946 hasAuthorship W2128421946A5091855331 @default.
• W2128421946 hasConcept C126322002 @default.
• W2128421946 hasConcept C126894567 @default.
• W2128421946 hasConcept C142724271 @default.
• W2128421946 hasConcept C197934379 @default.
• W2128421946 hasConcept C204787440 @default.
• W2128421946 hasConcept C27081682 @default.
• W2128421946 hasConcept C2776312127 @default.
• W2128421946 hasConcept C2777333188 @default.
• W2128421946 hasConcept C2778164427 @default.
• W2128421946 hasConcept C2778375690 @default.
• W2128421946 hasConcept C2778941218 @default.
• W2128421946 hasConcept C2779502394 @default.
• W2128421946 hasConcept C2991744798 @default.
• W2128421946 hasConcept C71924100 @default.
• W2128421946 hasConcept C77411442 @default.
• W2128421946 hasConceptScore W2128421946C126322002 @default.
• W2128421946 hasConceptScore W2128421946C126894567 @default.
• W2128421946 hasConceptScore W2128421946C142724271 @default.
• W2128421946 hasConceptScore W2128421946C197934379 @default.
• W2128421946 hasConceptScore W2128421946C204787440 @default.
• W2128421946 hasConceptScore W2128421946C27081682 @default.
• W2128421946 hasConceptScore W2128421946C2776312127 @default.
• W2128421946 hasConceptScore W2128421946C2777333188 @default.
• W2128421946 hasConceptScore W2128421946C2778164427 @default.
• W2128421946 hasConceptScore W2128421946C2778375690 @default.
• W2128421946 hasConceptScore W2128421946C2778941218 @default.
• W2128421946 hasConceptScore W2128421946C2779502394 @default.
• W2128421946 hasConceptScore W2128421946C2991744798 @default.
• W2128421946 hasConceptScore W2128421946C71924100 @default.
• W2128421946 hasConceptScore W2128421946C77411442 @default.
• W2128421946 hasIssue "3" @default.
• W2128421946 hasLocation W21284219461 @default.
• W2128421946 hasLocation W21284219462 @default.
• W2128421946 hasOpenAccess W2128421946 @default.
• W2128421946 hasPrimaryLocation W21284219461 @default.
• W2128421946 hasRelatedWork W2005256857 @default.
• W2128421946 hasRelatedWork W2010625829 @default.
• W2128421946 hasRelatedWork W2128421946 @default.
• W2128421946 hasRelatedWork W2591436981 @default.
• W2128421946 hasRelatedWork W2606250578 @default.
• W2128421946 hasRelatedWork W3142038880 @default.

• next